Clinical Trials
Braintumor Website

 For People with Newly Diagnosed Glioblastoma Multiforme
A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM)
With Epidermal Growth Factor Receptor (EGFR) Amplification

 For People with Reccurent Glioblastoma Multiforme (and other malignant gliomas)
A Study of ABT-414 in Adult or Pediatric Subjects With Recurrent Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Glioblastoma at First Recurrence or Progression
Aldoxorubicin Trial for recurrent GBM.

These trials were the most recently added or updated

NCT Trial Name# of CentersLast Updated

NCT03233204

  Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
5704/02/2018

NCT03220035

  Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
4104/02/2018

NCT03213665

  Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
4404/02/2018

NCT03155620

  Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
8704/02/2018

NCT02993146

  Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
604/02/2018

NCT01922076

  WEE1 Inhibitor AZD1775 and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
1704/02/2018

NCT01849146

  Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma
504/02/2018

NCT01604512

  A Comparison of MRI Perfusion and FDG PET/CT to Distinguish Between Radiation Injury and Tumor Progression
604/02/2018

NCT03412877

  Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer
103/31/2018

NCT03190967

  T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
103/31/2018

NCT01986348

  A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas
103/31/2018

NCT03246113

  Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma
103/30/2018

NCT01445483

  Neuropsychological Changes in Patients Receiving Radiation Therapy for Brain Metastases
103/30/2018

NCT03330197

  A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors or DIPG
203/29/2018

NCT03213704

  Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
6403/29/2018

NCT02133183

  Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma
703/29/2018



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740